The abstract is read at the publisher; the summary is JClub's.
A response-adapted surgery strategy after neoadjuvant immunochemotherapy in HPV-negative stage III–IVA LA-HNSCC achieved 83% 2-year disease-free survival and enabled 100% laryngeal preservation in the reduced-volume group.
- Why it matters: Standard surgery after neoadjuvant treatment can be morbid, and it is unclear whether tailoring surgical extent to early tumor regression can maintain oncologic outcomes while preserving function.
- What they did: In this single-arm phase II trial, 50 patients received three cycles of penpulimab, nab-paclitaxel, and cisplatin, then underwent reduced-volume surgery if primary tumor regression was ≥50% on pre-cycle 3 imaging and laryngoscopy, otherwise standard-volume surgery.
- The result: Per-protocol 2-year DFS was 83% (95% CI, 69%–91%), with 90% (95% CI, 77%–96%) in the reduced-volume group (n=42) versus 20% (95% CI, 0.8%–58%) in the standard-volume group (n=5), and no grade 4–5 AEs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.